• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Research in Oncology
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 20 (2024)
Volume Volume 19 (2023)
Issue Issue 2
Issue Issue 1
Volume Volume 18 (2022)
Volume Volume 17 (2021)
Volume Volume 16 (2020)
Volume Volume 15 (2019)
Volume Volume 14 (2018)
Volume Volume 13 (2017)
Volume Volume 12 (2016)
Mahmoud, A., Metwally, E., Balata, R., Khater, A., Abdullah, R., Abutaleb, F. (2023). The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma. Research in Oncology, 19(1), 6-12. doi: 10.21608/resoncol.2023.173693.1180
Asmaa A. Mahmoud; Elsayed A. Metwally; Rawda Balata; Amira I. Khater; Rania M. Abdullah; Fouad M. Abutaleb. "The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma". Research in Oncology, 19, 1, 2023, 6-12. doi: 10.21608/resoncol.2023.173693.1180
Mahmoud, A., Metwally, E., Balata, R., Khater, A., Abdullah, R., Abutaleb, F. (2023). 'The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma', Research in Oncology, 19(1), pp. 6-12. doi: 10.21608/resoncol.2023.173693.1180
Mahmoud, A., Metwally, E., Balata, R., Khater, A., Abdullah, R., Abutaleb, F. The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma. Research in Oncology, 2023; 19(1): 6-12. doi: 10.21608/resoncol.2023.173693.1180

The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma

Article 2, Volume 19, Issue 1, June 2023, Page 6-12  XML PDF (177.44 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2023.173693.1180
View on SCiNiTO View on SCiNiTO
Authors
Asmaa A. Mahmoud email orcid 1; Elsayed A. Metwally2; Rawda Balataorcid 3; Amira I. Khater4; Rania M. Abdullah5; Fouad M. Abutaleb1
1Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2Hematology Unit, Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt
5Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Abstract
Background: More research is ongoing on obesity as a risk factor for cancer occurrence.Cell of origin (COO), stage and National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) are frequently used for risk evaluation and treatment tailoring in patients with Diffuse large B-cell lymphoma (DLBCL). Relatively, few studies assessed the prognostic role of obesity and leptin level in patients with DLBCL.
Aim: The aim of this study was to investigate the effect of obesity and leptin level on response and prognosis in DLBCL. Methods: A single institution prospective study that included patients with DLBCL. For each patient, demographic data, body mass index (BMI), serum leptin level by ELISA, response and survival were determined.
Results: Seventeen (24.3%) out of the 70 patients in our cohort were classified as obese (BMI>30). They had a higher serum leptin level (p < 0.001) and less response to R-CHOP chemotherapy (P= 0.003). Forty (57.14%) patients had elevated serum leptin level with B symptoms, Cell of origin and response to chemotherapy were significantly different between the two groups.  There was no significant relationship between BMI and survival. On the other hand, higher serum leptin was associated with worse disease-free survival (p=0.035).
Conclusion: The results support a relationship between both BMI and serum leptin level and response to treatment in DLBCL patients. Leptin level like other common prognostic factors is related to disease-free survival.
Keywords
Body mass index; Diffuse large B-cell lymphoma; Leptin; Prognosis
Statistics
Article View: 442
PDF Download: 486
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.